Nemaura’s SugarBEAT Non-Invasive CGM Earns CE Mark
SugarBEAT is a non-invasive, needle-free, disposable adhesive skin-patch connected to a rechargeable transmitter. The company says it is the world’s first non-invasive continuous glucose monitor.
You may also be interested in...
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week’s approvals include the US FDA's approval of a panel-track supplement for TransMedics' OCS Lung system to preserve donor lungs that would not be salvageable using a traditional cold static system.
Results Recap: Post-Market Results From Avinger's Pantheris Peripheral OCT System; Nemaura Announces sugarBEAT CGM Results
This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from Meddevicetracker.com, includes preliminary analysis of results from Avinger's SCAN clinical study, a 12-patient, 240-image post-market study of Avinger's Pantheris optical coherence tomography in the peripheral arteries and results of an 18-patient early-feasibility study showing Nativis' Voyager device is safe for treatment of recurrent glioblastoma.
The company’s leadership discussed its recent investments in robotic surgery technology during Johnson & Johnson’s 2019 fourth-quarter earnings call on 22 January. The company will provide more information on its robotic surgery platforms at its investors meeting in May in New York.